TW202332473A - 放射性核種複合物的組合療法 - Google Patents

放射性核種複合物的組合療法 Download PDF

Info

Publication number
TW202332473A
TW202332473A TW111140975A TW111140975A TW202332473A TW 202332473 A TW202332473 A TW 202332473A TW 111140975 A TW111140975 A TW 111140975A TW 111140975 A TW111140975 A TW 111140975A TW 202332473 A TW202332473 A TW 202332473A
Authority
TW
Taiwan
Prior art keywords
dota
weeks
day
dose
subject
Prior art date
Application number
TW111140975A
Other languages
English (en)
Chinese (zh)
Inventor
保拉 丹尼拉 艾蒙
戴妮娜 奇可
馬里西歐 F 馬里亞尼
艾芙任 索兒
Original Assignee
瑞士商諾華公司
法商高級催化劑應用品有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司, 法商高級催化劑應用品有限公司 filed Critical 瑞士商諾華公司
Publication of TW202332473A publication Critical patent/TW202332473A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW111140975A 2021-10-27 2022-10-27 放射性核種複合物的組合療法 TW202332473A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163272447P 2021-10-27 2021-10-27
US63/272,447 2021-10-27

Publications (1)

Publication Number Publication Date
TW202332473A true TW202332473A (zh) 2023-08-16

Family

ID=84365353

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111140975A TW202332473A (zh) 2021-10-27 2022-10-27 放射性核種複合物的組合療法

Country Status (11)

Country Link
US (1) US20250387523A1 (enExample)
EP (1) EP4422701A1 (enExample)
JP (1) JP2024539952A (enExample)
KR (1) KR20240093832A (enExample)
CN (1) CN118159304A (enExample)
AU (1) AU2022374887A1 (enExample)
CA (1) CA3234495A1 (enExample)
IL (1) IL312106A (enExample)
MX (1) MX2024004961A (enExample)
TW (1) TW202332473A (enExample)
WO (1) WO2023073603A1 (enExample)

Also Published As

Publication number Publication date
US20250387523A1 (en) 2025-12-25
CA3234495A1 (en) 2023-05-04
CN118159304A (zh) 2024-06-07
WO2023073603A1 (en) 2023-05-04
AU2022374887A1 (en) 2024-04-11
MX2024004961A (es) 2024-05-08
JP2024539952A (ja) 2024-10-31
IL312106A (en) 2024-06-01
EP4422701A1 (en) 2024-09-04
KR20240093832A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
JP7839135B2 (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法(trt)の使用
JP2024541595A (ja) 放射線医薬的治療方法及び使用
Chen et al. Development of [177Lu] Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma
CN119095629A (zh) 用于癌症患者的诊断方法
JP2026505341A (ja) 神経膠芽腫を治療するための方法
WO2024176147A1 (en) Methods for treating breast cancer
US20240050597A1 (en) Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent
Nedelcovych et al. JHU-2545 selectively shields salivary glands and kidneys during PSMA-targeted radiotherapy
US20250387523A1 (en) Combination therapy of radionuclide complex
WO2010117992A2 (en) Coupled identification and treatment of cancer
US20240042067A1 (en) [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof
KR20250109190A (ko) 암의 식별 및/또는 치료
WO2025126151A1 (en) Methods for treating breast cancer
KR20260014588A (ko) 전립선암의 진단 및/또는 치료 방법